Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy

Clinical Infectious Diseases

Volumn 38, Issue 3, 2004, Pages 433-437

  Zaccarelli, Mauro ^a   Perno, Carlo Federico ^a   Forbici, Federica ^a   Soldani, Fabio ^a   Bonfigli, Sandro ^a   Gori, Caterina ^a   Trotta, Maria Paola ^a   Bellocchi, Maria Concetta ^a   Liuzzi, Giuseppina ^a   D'Arrigo, Roberta ^a   De Longis, Patrizio ^a   Boumis, Evangelo ^a   Bellagamba, Rita ^a   Tozzi, Valerio ^a   Narciso, Pasquale ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; T LYMPHOCYTE; TREATMENT FAILURE;

ADULT; DRUG RESISTANCE, MULTIPLE; FEMALE; GLUTAMINE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MALE; METHIONINE; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SALVAGE THERAPY;

EID: 10744229965     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381097     Document Type: Article

References (20)

1. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 1995; 270: 23605-11.
2. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169:722-9.
3. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 1995; 172:70-8.
4. Van Vaerenbergh K, Debaisieux L, De Cabooter N, et al. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antivir Ther 2001; 6:63-70.
5. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1015-20.
6. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-90.
7. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-61.
8. Schmit JC, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12:2007-15.
9. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44:2109-17.
10. Re MC, Borderi M, Monari P, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs. Int J Antimicrob Agents 2001; 18:519-23.
11. Balotta C, Violin M, Monno L, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J Acquir Immune Defic Syndr 2000; 24:232-40.
12. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2003; 37:113-28.
13. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 1999; 13:1705-9.
14. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-15.
15. Mouroux M, Descamps D, Izopet J, et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 2001; 6: 179-83.
16. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002; 16:1686-9.
17. Miller V, Sturmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-12.
18. Zaccarelli M, Perno CF, Forbici F, et al. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther 2003; 8:51-6.
19. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-70.
20. Walter H, Low P, Harrer T, et al. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. J Acquir Immune Defic Syndr 2002; 31: 137-46.